gene expression regulators that not only have been described as being involved in crucial biological processes, including development, differentiation, apoptosis and proliferation control, but also have been proposed as contributing to oncogenesis, either as tumor suppressors or as oncogenes (reviewed by Calin and Croce 5 ). We report here the results of our investigation into the loss of the miRNAs at 7q32 as a potential clue for the upregulation of the genes involved in SMZL oncogenesis.
To this end, we quantified the expression of the two most distal miRNAs located in the minimal CDR (hsa-mir-29a, and hsa-mir-29b-1) in 20 consecutively diagnosed cases of SMZL and seven non-SMZL low-grade B-cell lymphomas with splenic involvement: one follicular lymphoma, two mantle cell lymphoma and four chronic lymphocytic leukemia (CLL) for comparative purposes. Six reactive splenic tissue cases (four arising from traumatic rupture and two diagnosed with idiopathic thrombocytopenic purpura) were included in the present study. These were selected from routine and consultation cases of the Centro Nacional de Investigaciones Oncoló gicas (CNIO), Hospital Virgen de la Salud, Toledo and the Spanish Tumor Bank Network. Research was performed under the supervision of the Institutional Review Board of the Hospital Virgen de la Salud, Toledo, Spain. Cases were diagnosed on the basis of splenic morphology, immunophenotypical and molecular findings, following the criteria described in the World Health Organization Lymphoma classification.
Total RNA was extracted using Trizol reagent (GIBCO Life Technologies, Grand Island, NY, USA) from 32 frozen blocks of splenectomy specimens (20 SMZL, seven non-SMZL lowgrade B-cell lymphomas and five control spleens) and from splenic-sorted B-cells obtained from one fresh non-tumoral spleen specimen by magnetic depletion of non-B-cells, as recommended by the manufacturer (MACS B Cell Isolation Kit II, Miltenyi Biotech, Auburn, CA, USA).
To measure the expression of mature forms of the miRNAs, real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed with mirVanaTM qRT-PCR miRNA Detection Kit (Ambion Inc., Austin, TX, USA) The 5 s endogenous control gene was chosen, not only on the basis of its homogeneous expression in all splenic specimens, but also as a representative of the quality of the small-fraction RNAs. All PCRs were performed using the ABI Prism 7500 (Applied Biosystems, Foster City, CA, USA) under the conditions recommended by the manufacturer, and the results were normalized and analyzed using sequence-detection software (Applied Biosystems Foster City, CA, USA). Data are presented as the fold change in miRNA expression in tumors relative to the normal tissue control pool (matched normal as calibrator) using the 2-WWC T method. As spleens with lymphoma contain a variable proportion of non-tumoral cells, we included the expression data from sorted-splenic B cells to control for this bias.
We studied Tcl1 protein expression by immunohistochemical analysis using the TechMate 500 (DAKO) automatic immunostaining device. The antibody used was the clon 27D6/20 from MBL. For antigen-retrieval techniques, a previous step of pressure cooker heating in a solution of 10 mM sodium citrate buffer was performed. Immunodetection was performed with peroxidaselabeled streptavidin biotin (LSAB, DAKO, Copenhagen, Denmark), using diaminobenzidine chromogen as substrate.
The expression data are summarized in Table 1 , cytogenetic and loss of heterozygosity (LOH) data 1 for 7q31-32 in this SMZL series were included, when available.
They show that levels of miRNA expression in the SMZL series are uniformly lower than those of the control splenic B-cells with only two exceptions, and are independent of the presence of 7q LOH (Figure 1a ). This result implies that there could be losses in the two copies of 7q, which may result not only from deletion, but also from the occurrence of other processes such as methylation and/or mutation. In fact, these molecules are clustered in islands that are highly susceptible to methylation, and mutation phenomena have been described in some cases of B-cell chronic lymphocytic leukemia. 6 Additionally, it is possible to see that the expression of the miRNAs hsa-mir-29a and hsamir-29b-1 is correlated (Spearman's r ¼ 0.9; Po0.01), supporting the results of a recent study using leukemia cell lines. 7 There is a distinct tendency for the miRNAs analyzed here to be lost in SMZL series, and to be variably expressed in the other B-cell lymphomas involving the spleen (Figure 1a) . In fact, our measures of miRNA expression differ significantly between the two groups (t-test; Po0.05), being lower in SMZL cases (Figure 1b) .
Finally, we investigated whether those miRNAs located in the minimal CDR could have a potential role on the induction of the SMZL signature.
Using the web resource miRBase Targets (Release 4) (http:// microrna.sanger.ac.uk/targets/v4/), a computational protocol based on the sequences included in the miRNA registry and its homologies with gene promoters, we found that hsa-mir-29b-1 followed by hsa-mir-29a were the best candidates for regulating one of the most over-expressed genes found in the SMZL molecular signature, TCL1A. 2 In fact, overexpression of Tcl1 protein was found in 14/19 cases analyzed here, this confirming previous observations. 2 The study suggests that TCL1A deregulation may be caused by faulty gene silencing as a potential consequence of losses of 7q miRNAs, a finding that would require experimental confirmation. These observations are consistent with what has recently been demonstrated in CLL cells. 8 Further investigations are needed to reveal the mechanisms leading to the 7q32 miRNAs loss, and their interaction with TCL1A in SMZL entity. Table 1 for the entire series including the non-marginal splenic B-cell lymphoma group. Red and blue indicate higher and lower expression, respectively. (b) Graph of the comparation between the mean of expression in each group of lymphomas analyzed here.
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